GLP-1 medications have completely changed the way many patients and clinicians think about weight and metabolic health. Agents like semaglutide and tirzepatide have moved from specialist conversations into everyday primary care, fueled by striking clinical trial results and constant media coverage. Patients often arrive with stories of friends or celebrities who “lost 30 pounds” and want to know how quickly they can expect the same outcome.
The first challenge is recalibrating expectations. GLP-1s are powerful, but they are still medications with titration schedules, side effects, and ceilings. Nausea and other GI symptoms are common, especially early on, and oftentimes additional medications are necessary for symptomatic management. Moreover, responses and tolerability may vary. Some patients see rapid changes and have minimal symptoms, whereas others make progress slowly, and some will never tolerate the medication altogether. A discussion of strength training is essential too, as patients who neglect to maintain anabolic growth signals through the use of their muscles may lose valuable muscle mass, a concern that grows more harmful with advancing age.
Long-term planning is essential, as metabolic disease is a chronic, relapsing condition. Framing these drugs as long-term metabolic therapies rather than instant fixes helps align patients with the real arc of treatment. Just as patients are advised that their anti-hypertensive or lipid-lowering therapies are most likely to be taken indefinitely, a similar conversation should not be forgotten when discussing GLP-1s. It is important to set expectations about what might happen when patients stop the medication, how lifestyle changes fit into the picture, and what obstacles might stand in the way of ongoing therapy. Without this framing, patients may feel discouraged if weight returns after discontinuation or if long-term use is not feasible, highlighting the second major challenge associated with GLP-1s: access.
Coverage for obesity indications remains inconsistent. Two patients with nearly identical clinical profiles may receive completely different insurance decisions depending on plan design and timing. Formularies can change mid-year, and shortages can interrupt ongoing therapy. Clinicians frequently find themselves explaining why the diabetes-indicated brand name may be covered while the obesity-indicated brand name of the same molecule is not.
Patients also sometimes need help understanding the differences between GLP-1 and GIP/GLP-1 combinations. Tirzepatide’s dual agonism, for example, is gaining attention as “the next step up,” but emerging data suggest it may be better to start with it in the first place. A head to head randomized trial showed that tirzepatide causes less gastrointestinal side effects than semaglutide, albeit at the expense of increased infusion-site reactions. Despite tirzepatide’s apparent superiority to semaglutide and other GLP-1s, the unfortunate reality is that clinicians are often forced to prescribe less effective and less tolerable medications due to wide variations in coverage and availability.
